CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH In this phase 1-2 study, patients with triple-class-exposed relapsed or refractory multiple myeloma experienced a high proportion of profound and long-lasting responses to teclistamab. Infections and cytopenias were frequent, and most grade 1 or 2 toxicities were consistent with T-cell misdirection.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
